Genedrive Share Discussion Threads

[chatchat] 26/7/2024 14:19

Batiatus

From your post 341 where I highlighted that £6m funding is already in the GDR bank account.

" Chatchat, good post. At least some information about GDR and their plans".

[premium beeks] 26/7/2024 14:19

Afternoon all. Well rested and ready for a long weekend away from the boards. Please all try to take time out and relax whilst the markets are closed, nothing can be done about positions anyway.

[hazl] 26/7/2024 14:13

However always appreciate people's charts.
Whilst not written in stone always interesting.

[batiatus] 26/7/2024 14:13

Trading error is buying in without full confirmation of NICE and funding strategy

[hazl] 26/7/2024 14:12

GTo be honest nobody makes us press the button or decide not to.
We have to be responsible for our own decisions.

[z1co] 26/7/2024 13:57

Soci ,

That's a NICE CHART saying 6p i believe

Approval confirmation i expect a lot higher

[socionomics] 26/7/2024 13:52

Just my latest short term view:



Staying off the forums for a while. Made a significant trading error yesterday as a result of Beeks' mind-games.

[z1co] 26/7/2024 13:50

This BLATANT LIAR has posted that the company does NOT have any products approved when in fact MT-RNR1 ID Kit was approved last year and is being sold to hospitals.

How could anyone trust such a BLATANT LIAR , his latest post above is of no real substance.

On yer bike

[batiatus] 26/7/2024 13:38

MM's will take the price sharply lower in the last 30 minutes of trading.

Quite a few trigger happy traders were very happy to be sucked in.

[z1co] 26/7/2024 13:29

MM's will take the price sharply higher in the last 30 minutes of trading.

Quite a few trigger happy traders gave their shares away far too cheaply.

[z1co] 26/7/2024 13:16

The publication will be on 31/07/2024 as per NICE web page.

Next Wednesday and NOT on Monday

[hazl] 26/7/2024 13:14

31st It is.

[z1co] 26/7/2024 13:06

The last paragraph is of significant importance if NICE were not going to approve CYP2C19 ID Test then why would they say quote:

"NICE is working in partnership with colleagues at NHS England and NHS Improvement, to develop a resource to support the implementation which will publish alongside the final guidance."

[albert35911] 26/7/2024 12:58

Maybe approve tests Monday,,,who knows?

[z1co] 26/7/2024 12:50

Big Daddy

The next thread i create i will be able to moderate your pathetic post completely.

Well do you have anything USEFUL to post about the company or it's products or even about the outcome next week.

We will soon find out what DADDY has to say.

Please could you NOT take too long!!!

LOLOL

[z1co] 26/7/2024 12:44

Again MM's drop the offer to 4.15p but won't let you buy a bean.

[minja19] 26/7/2024 12:44

4.28 resistance, still a hurdle.
considerably more volume required, (40m plus, my estimate) and then we'll be on our way

[z1co] 26/7/2024 12:41

Ahhhh bless you must be talking about yourself.

We already new that a long time ago

Any thing useful to post about the company rather than an IDIOTIC remark

[daddy warbucks] 26/7/2024 12:39

I've suddenly found out what ADVFN stands forADiversionary ViewpointForNutters

[z1co] 26/7/2024 12:36

Lunch time traders selling for small profits to buy their MEAL DEALS!!

10p + upon approval.

Last year the price increased to nearly 50p when NICE approved MT-RNR1 ID Kit

[z1co] 26/7/2024 12:31

On the basis of what NICE has said APPROVAL IS A CERTAINTY:

In addition to being dominant in cost effectiveness models, NICE recommends the Genedrive® as the point-of-care platform of choice for CYP2C19 genotyping strategies in the NHS. The decision was based on several differentiating features of the Genedrive® technology;

1) its greater coverage of genetic variants compared to the other point-of-care system assessed, permitting increased equitable access to healthcare across ethnic populations

2) no requirement for cold-chain storage logistics

3) its ability to integrate with patient electronic healthcare systems.

The UK's National Institute for Health and Care Excellence ("NICE") has recommended in draft guidance, that the Genedrive® CYP2C19-ID test should be used as the point-of-care test of choice in the NHS before clopidogrel administration in the management of IS and TIA patient

Resolution has now concluded, so we plan to publish as soon as we can. NICE is working in partnership with colleagues at NHS England and NHS Improvement, to develop a resource to support the implementation which will publish alongside the final guidance.

[z1co] 26/7/2024 12:28

ON YER BIKE LIAR